


Antiarrhythmic Drugs



Contents



Definition and mechanisms of arrhythmias

Physiology of normal cardiac rhythm

Electrophysiology-Rhythmicity

Types of arrhythmias

Causes of arrhythmias

Mechanism of arrhythmias

- Cardiac arrhythmia is an abnormality of the heart rhythm
- *Bradycardia* – heart rate slow (<60 beats/min)
- *Tachycardia* – heart rate fast (>100 beats/min)

Arrhythmia


Heart condition where disturbances in-

- Pacemaker impulse formation
- Contraction impulse conduction
- Combination of the two

Results in rate and/or timing of contraction of heart muscle that is insufficient to maintain normal cardiac output (CO)


Physiology of cardiac rate and rhythm

- Cardiac myocytes are **electrically excitable**
- Resting intracellular voltage of myocardial cells is negative -90mV (SA node is -40mV)
- Resting state - K^+ inside and Na^+ outside cell (Na^+/K^+ pump)
- **Action potential** occurs when Na^+ enters the cell and sets up a depolarising current
- Stimulation of a single muscle fibre causes electrical activity to spread across the myocardium




Phases of action potential of cardiac cells

- **Phase 0** rapid depolarisation (inflow of Na^+)
- **Phase 1** partial repolarisation (inward Na^+ current deactivated, outflow of K^+)
- **Phase 2** plateau (slow inward calcium current)
- **Phase 3** repolarisation (calcium current inactivates, K^+ outflow)
- **Phase 4** pacemaker potential (Slow Na^+ inflow, slowing of K^+ outflow)
'autorhythmicity'
- **Refractory period** (phases 1-3)




Normal heartbeat and atrial arrhythmia


Normal rhythm



Atrial arrhythmia



ECG (EKG) showing wave segments




Electrocardiogram(ECG)

- Recording of electrical activity of the heart
- Net sum of depolarisation and repolarisation potentials of all myocardial cells
- P-QRS-T pattern
- P - atrial depolarisation
- QRS -ventricular depolarisation
- T - ventricular repolarisation

Ventricular Arrhythmia

- Ventricular arrhythmias are common in most people and are usually not a problem but...
- VA's are most common cause of sudden death
- Majority of sudden death occurs in people with neither a previously known heart disease nor history of VA's
- Medications which decrease incidence of VA's do not decrease (and may increase) the risk of sudden death → treatment may be worse than the disease!




Disorders of impulse formation

- ❖ No signal from the pacemaker site
- ❖ Development of an ectopic pacemaker
 - May arise from conduction cells (most are capable of spontaneous activity)
 - Usually under control of SA node → if it slows down too much conduction cells could become dominant
 - Often a result of other injury (ischemia, hypoxia)
- ❖ Development of oscillatory afterdepolarizations
 - Can initiate spontaneous activity in non-pacemaker tissue
 - May be result of drugs (digitalis, nor-epinephrine) used to treat other cardiopathologies.

Disorders of impulse conduction

- May result in
 - Bradycardia (if have AV block)
 - Tachycardia (if reentrant circuit occurs)



Reentrant
circuit

- A transmembrane electrical gradient (potential) is maintained, with the interior of the cell negative with respect to outside the cell
- Caused by unequal distribution of ions inside vs. outside cell
 - Na^+ higher outside than inside cell
 - Ca^+ much higher “ “ “ “
 - K^+ higher inside cell than outside
- Maintenance by ion selective channels, active pumps and exchangers

Sinus rhythm

- Sinoatrial node is cardiac pacemaker
- Normal sinus rhythm 60-100 beats/min
- Depolarisation triggers
 - depolarisation of atrial myocardium ('forest fire')
- Conducts more slowly through AV node
- Conducts rapidly through His bundles and Purkinje fibres



Sinus rhythm

- Sinoatrial rate controlled by autonomic nervous system
- Parasympathetic system predominates (M₂ muscarinic receptors)
- Sympathetic system (β_1 receptors)
 - Increased heart rate (positive chronotropic effect)
 - Increased automaticity
 - Facilitation of conduction of AV node

- Cardiac ischemia
- Excessive discharge or sensitivity to autonomic transmitters
- Exposure to toxic substances
- Unknown etiology



Mechanisms of arrhythmia production

- Result from disorders of impulse formation, conduction, or both as:


Re-entry (refractory tissue reactivated due to conduction block, causes abnormal continuous circuit. eg accessory pathways linking atria and ventricles in Wolff-Parkinson-White syndrome)

Abnormal pacemaker activity in non-conducting/conducting tissue (eg ischaemia)

Delayed after-depolarisation (automatic depolarisation of cardiac cell triggers ectopic beats, can be caused by drugs eg digoxin)

Vaughan Williams classification of antiarrhythmic drugs

- **Class I:** block sodium channels
 - Ia (quinidine, procainamide, disopyramide)
 - Ib (lignocaine, phenytoin)
 - Ic (flecainide, propafenone)
- **Class II:** β -adrenoceptor antagonists (propranolol, atenolol, sotalol)
- **Class III:** prolong action potential and prolong refractory period (suppress re-entrant rhythms) (amiodarone, dronedarone)
- **Class IV:** Calcium channel antagonists. Impair impulse propagation in nodal and damaged areas (verapamil, diltiazem)




Class I; sodium channel blockers

- ▶ Membrane stabilizing agents.
- ▶ These classes of drugs are local anesthetics acting on nerve & myocardial membranes to slow conduction by inhibiting phase 0 of action potential.
- ▶ They decrease the maximal rate of depolarisation without changing the resting potential.
- ▶ Class I is subclassified into three class:-class Ia, class Ib, class Ic.

❑ Class Ia


- ▶ Quinidine



Quinidine


Class Ib

- ▶ lignocaine



Class Ic


- ▶ flecainide




➤ *Class-II ; Beta Blockers*

- Non-selective(β) : Propranolol, sotalol, atenolol

✓ propranolol structure ;



✓ atenolol




Beta Blockers:


- ▶ They depress automaticity, prolong A.V. Conduction ,reduce heart rate,and also decrease contractibility.

Class III drugs

- ▶ Amiodarone(HCl)




Dronedarone(HCl)




- These drugs cause a homogeneous prolongation of duration of action potential.
- ▶ These results in a prolongation of the effective refractory period.
- ▶ They act through phase 3 of action potential by blocking potassium channels

Class IV; Calcium channel blockers

- ▶ They causes a prolongation of refractory period in the AV node and the atria, a decrease in atrioventricular conduction, & a decrease in spontaneous diastolic depolarisation.
- ▶ These effects block conduction of premature impulses at AV node & thus very effective in treating supraventricular arrhythmias.



Verapamil




Diltiazem

Recent advance in arrhythmia


□ Vernakalant

Vernakalant




- ▶ It act selectively on atrium by only delaying atrial repolarization.
- ▶ It does this by selectively acting on K^+ channels that exist primarily in atrium, thus resulting in atrial specific prolongation of effective refractory period.

Dofetilide




- ▶ Novel Class III antiarrhythmic agent.
- ▶ It act by selective prolongation of cardiac action potential duration.
- ▶ It works by selectively blocking the rapid component of delayed rectified outward potassium current.
- ▶ USE-atrial fibrillation,atrial flutter & PSVT.

LANDIOLOL




- It is a new ultra-short acting beta blocker, in patient with cardiac tachyarrhythmias.

AZIMILIDE DIHYDROCHLORIDE




- ▶ Novel Class III antiarrhythmic agent.
- ▶ USE;atrial fibrillation,atrial flutter & paroxysmal supraventricular tachycardia in patient with and without structural heart disease.

Nifekalant hydrochloride




- ▶ Novel Class III antiarrhythmic agent.
- ▶ No selective blocker of myocardial repolarising potassium currents & completely devoid of β adrenergic effect.

• *E-4031*




- ▶ Novel Class III antiarrhythmic agent.
- ▶ It is synthesized toxin that is methane sulfonamide.

❖ *Tecadenoson(CVT-510)*



- ▶ It is novel selective adenosine receptor antagonist, selectively activates A1 adenosine receptor & prolongs AV node conduction at doses lower than those required to cause A2 adenosine receptor mediated coronary & peripheral vasodilation.

❖ *Ibutilide*



- ▶ Novel Class III antiarrhythmic agent.
- ▶ At a cellular level it exerts two actions; induction of a persistent Na⁺ current sensitive to dihydropyridine Ca²⁺ channel blockers & potent inhibition of cardiac rapid delayed rectifier K⁺ current, by binding within the channel pore cavity upon channel gating.

A blue spotlight beam shines down from the top center of the frame, creating a circular pool of light on a dark surface. The words "THANK YOU" are written in a bold, white, sans-serif font with a blue outline, positioned within the spotlight. The text is slightly curved to follow the shape of the light pool. Below the text, a dark, reflective surface shows a faint, inverted reflection of the words.

THANK YOU

THANK YOU